Protagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million

Reuters03-09

Protagenic <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million

Protagenic reported a loss from operations of USD 0.93 million for Q3 ended Dec. 31, 2025, widening 130% from a year earlier. Legal fees rose to USD 0.22 million, up 565%, and general and administrative expenses increased to USD 0.15 million, up 212%. For the nine months ended Dec. 31, 2025, loss from operations was USD 4.38 million, up more than tripled, while research and development expense increased to USD 0.82 million, up 381%. Operating activities used USD 3.07 million in cash for the nine months, and cash was USD 2.21 million as of Dec. 31, 2025. The company said it expects its cash resources to fund operations until approximately the end of Q2 FY 2027 (quarter ending Sept. 30, 2026).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-009301), on March 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618623176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618623176","market":"nz","top_or_hot":-1,"title":"Protagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protagenic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Protagenic reported a loss from operations of USD 0.93 million for Q3 ended Dec. 31, 2025, widening 130% from a year earlier. Legal fees rose to USD 0.22 million, up 565%, and general and administrative expenses increased to USD 0.15 million, up 212%. For the nine months ended Dec. 31, 2025, loss from operations was USD 4.38 million, up more than tripled, while research and development expense increased to USD 0.82 million, up 381%. Operating activities used USD 3.07 million in cash for the nine months, and cash was USD 2.21 million as of Dec. 31, 2025. The company said it expects its cash resources to fund operations until approximately the end of <a href=\"https://laohu8.com/S/QTWO\">Q2</a> FY 2027 (quarter ending Sept. 30, 2026).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-009301), on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-09 19:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Protagenic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Protagenic reported a loss from operations of USD 0.93 million for Q3 ended Dec. 31, 2025, widening 130% from a year earlier. Legal fees rose to USD 0.22 million, up 565%, and general and administrative expenses increased to USD 0.15 million, up 212%. For the nine months ended Dec. 31, 2025, loss from operations was USD 4.38 million, up more than tripled, while research and development expense increased to USD 0.82 million, up 381%. Operating activities used USD 3.07 million in cash for the nine months, and cash was USD 2.21 million as of Dec. 31, 2025. The company said it expects its cash resources to fund operations until approximately the end of <a href=\"https://laohu8.com/S/QTWO\">Q2</a> FY 2027 (quarter ending Sept. 30, 2026).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-009301), on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTIX","symbol_name":"Protagenic Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLqbXBH:1","article_id":"2618623176","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618623176","pubTimestamp":1773056824,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Protagenic reported a loss from operations of USD 0.93 million for Q3 ended Dec. 31, 2025, widening 130% from a year earlier. Legal fees rose to USD 0.22 million, up 565%, and general and administrative expenses increased to USD 0.15 million, up 212%. For the nine months ended Dec. 31, 2025, loss from operations was USD 4.38 million, up more than tripled, while research and development expense increased to USD 0.82 million, up 381%. Operating activities used USD 3.07 million in cash for the nine months, and cash was USD 2.21 million as of Dec. 31, 2025. The company said it expects its cash resources to fund operations until approximately the end of Q2 FY 2027 .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTIX":"Protagenic Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Protagenic Therapeutics 2026财年第三季度运营亏损上升130%至93万美元，收入为75万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTIX":0.9},"content_text":"Protagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million\n    \n\n        Protagenic reported a loss from operations of USD 0.93 million for Q3 ended Dec. 31, 2025, widening 130% from a year earlier. Legal fees rose to USD 0.22 million, up 565%, and general and administrative expenses increased to USD 0.15 million, up 212%. For the nine months ended Dec. 31, 2025, loss from operations was USD 4.38 million, up more than tripled, while research and development expense increased to USD 0.82 million, up 381%. Operating activities used USD 3.07 million in cash for the nine months, and cash was USD 2.21 million as of Dec. 31, 2025. The company said it expects its cash resources to fund operations until approximately the end of Q2 FY 2027 (quarter ending Sept. 30, 2026).\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-009301), on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618623176","isCrawlerRequest":true}